2Kelly RA, Smith TW. Cytokmes and cardiac contractile functitm[J].Circulation, 1997,95(4) :778 - 781.
3Fessel WJ. High uric acid as an indicator of cardiovascular disease, indepencence from obesity[J]. Am J Med,1980,68(3):401 -404.
4Levya F, Anker SD,Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation[J]. Eur Heart J, 1998,19(12) :1746- 1747.
5Wassmann S, Faul A, Hennen B. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme, a reductase inhibition, on coronary endothelial function[J]. Circ Res, 2003,93(9) :98-103.
6Williams JK, Sukhova GK, Herrington DM, et al . Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys[J]. J Am Coll Cardiol,1998,31 : 684-691.
7Laufs U, La Fata V, Plutzky J, et al . Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J]. Circulation , 1998,97 : 1129-1135.
8Kureishi Y, Lou Z, Shiojima L, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals[J].Nat Med ,2000,6:1004-1010.
9Pelat M, Dessy C, Massion P, a al . Rosuvastatin decreases caveolin 1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo[J]. Circulation ,2003,107 : 2480-2486.
10Feron O, Dessy C, Desager JP, et al . Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance[J]. Circulation ,2001,89:866-873.
10Palomaki A, Malminiemi K, Solakivi T, et al. Ubiquinone supplementation during lovastatin treatment :effect on LDL oxidation ex vivo. J Lipid Res ,1998 ,39 (7) :1430- 1437.
